Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine, Oxaliplatin, and Gefitinib in Metastatic Colorectal Cancer
NCT00087334Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2004
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in metastatic colorectal cancer (mCRC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose and Response Rate. Started Jan 2004; status: terminated.
02
Drugs
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00087334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087334.